TP53 and tonsil cancer: In conclusion, the present study revealed that oncogenic/likely oncogenic mutations are relatively high in tonsil cancers, and that TP53 and RTK pathway mutations may be candidate predictors for detrimental prognosis in patients receiving adjuvant therapy and for overall tonsil cancer patients/HPV-positive subgroup, respectively, according to the AJCC eighth edition staging system.